Eton Pharmaceuticals Financials - Benzinga

Eton Pharmaceuticals Inc

ETONNASDAQ

Trade with Public

Trade with Public

$63.47

3.565.94%

At close: Aug 21, 5:00 PM EST

$63.94

0.470.74%

After Hours: Aug 21, 7:33 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Eton Pharmaceuticals Financials

Eton Pharmaceuticals (ETON) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Dow Falls Over 100 Points, Records Weekly Loss: Investor Sentiment Weakens, but Fear Index Remains in ‘Greed’ Zone

The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed zone. U.S. stocks closed lower, with the Dow Jones falling over 100 points.

Avi Kapoor

PRO
Eton Pharmaceuticals Q2 Adj. EPS $0.43 Beats $0.10 Estimate, Sales $37.568M Beat $27.119M Estimate

Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 290.91 percent. This is a 530 percent increase over losses of $(0.10) per share

Benzinga Newsdesk

PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $145.000M vs $121.326M Est

Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $145.000M vs $121.326M Est

Benzinga Newsdesk

PRO
Eton Pharmaceuticals FY2026 Revenue expected to be more than $120.000M vs $113.804M Est

Eton Pharmaceuticals (NASDAQ:ETON) FY2026 Revenue expected to be more than $120.000M vs $113.804M Est

Benzinga Newsdesk

PRO
Eton Pharmaceuticals Q1 Adj. EPS $0.14 Beats $0.09 Estimate, Sales $24.266M Beat $22.312M Estimate

Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.09 by 55.56 percent. This is a 100 percent increase over earnings of $0.07 per share from

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights